Dendreon Reaches Agreement for Valeant to Serve as “Stalking Horse Bidder” in Court-Supervised Sales ProcessJanuary 30, 2015 8:37 am | News | Comments
Under the terms of the agreement, Valeant would acquire the world-wide rights of PROVENGE® (...
Dendreon Corporation today announced that the company grew sales in four quarters successively,...
The maker of the prostate cancer treatment Provenge said in a Securities and Exchange Commission filing that there is a "significant risk" it will not be able to repay or refinance $620 million in notes due in 2016.
Dendreon Corporation announced that its board of directors has appointed W. Thomas Amick as president and chief executive officer, effective immediately. Mr. Amick has also been appointed to the company’s board of directors.
Dendreon Corporation today announced that it plans to make PROVENGE ® (autologous peripheral blood mononuclear cells activated with PAP-GM-CSF or sipuleucel-T) available in Europe, beginning with Germany and the United Kingdom.
Dendreon said that it no longer expects sales of its prostate cancer therapy Provenge to grow in 2013, and the company's shares slumped 13 percent in aftermarket trading. Net sales of Provenge decreased 8 percent in the second quarter and Dendreon's revenue from the drug fell 13 percent in the first half of the year.
Shares of Dendreon Corp. moved higher Monday after the company said sales of its prostate cancer therapy Provenge continued to grow in the fourth quarter. Provenge sales totaled $81.6 million, excluding special items. That's an improvement of 5 percent from the third quarter, and up 51 percent...
WASHINGTON (AP) — Shares of biotech developer Dendreon Corp. rose Friday after health insurer Aetna said it would expand coverage of Provenge, the company's pricey prostate cancer drug.
NEW YORK (AP) — Shares of Dendreon Corp. slumped Monday after Johnson & Johnson reported positive clinical data for a prostate cancer drug that competes with Dendreon's therapy Provenge.
NEW YORK (AP) — Shares of Dendreon Corp. sank Wednesday after a Jefferies & Co. analyst said the company's prostate cancer therapy Provenge will be eclipsed by two newer competitors.
WASHINGTON (AP) — Shares of biotech drugmaker Dendreon fell today on worries about an investigation into company conduct by financial regulators.
Dendreon tumbled more than 12 percent in premarket trading Tuesday after the drug developer reported a loss and what an analyst described as "modest growth" for the company's only marketed product, the prostate cancer treatment Provenge.
Dendreon said Tuesday that it sold its royalty interest in Merck & Co.’s hepatitis C drug Victrelis (boceprevir) for $125 million in a move that is expected to strengthen the company’s cash holdings.
SEATTLE (AP) — Dendreon Corp. said Thursday that it will eliminate 500 jobs, or more than a quarter of its work force, as it reduces costs to compensate for disappointing sales of its prostate cancer therapy Provenge.